Solutions for Healthcare Providers

iStent infinite^®

Can be Used in Patients Undergoing Cataract Surgery or a Standalone Procedure

The iStent infinite, is intended to reduce intraocular pressure safely and effectively in adult patients diagnosed with primary open-angle glaucoma, pseudo-exfoliative glaucoma or pigmentary glaucoma.

The device is safe and effective when implanted in combination with or without cataract surgery in those subjects who require intraocular pressure reduction and/or would benefit from glaucoma medication reduction.

The device may also be implanted in patients who continue to have elevated intraocular pressure despite prior treatment with glaucoma medications and/or conventional glaucoma surgery.

Learn more about studies

Go With the Flow—Rejuvenate the System

iStent infinite^® is designed to maximize outflow while minimizing disruption to natural anatomy by occupying only 3% of Schlemm’s canal, thereby leaving 97% untouched.

This, coupled with a patented multidirectional stent design, helps bypass resistance and restore physiologic outflow.

Intermediate Therapy That Excels Where Other Treatments Have Failed

In the prospective, multicenter, 12-month pivotal trial, patients with open-angle glaucoma who had failed prior surgical intervention underwent standalone iStent infinite^® implantation¹.

Despite this tough-to-treat population, iStent infinite^® delivered exceptional results demonstrating sustained efficacy throughout the course of the study, as well as exceptional intraoperative and postoperative safety¹.

View Clinical Data

Elegantly Precise Microsurgery

An elegant, precision-engineered injector system allows you to implant 3 wide-flange, anatomically designed stents across 180° of Schlemm’s canal.

200+ Peer-Reviewed Publications

iStent infinite^® carries on the legacy of excellence established by iStent^® devices over the last 20 years. It’s backed by the most robust, diverse, and longest-term body of clinical evidence for any MIGS procedure available today, driven through clinical rigor and integrity.

Optimized Outflow

Three multidirectional stents designed to restore natural outflow

Clinically Proven

Significant IOP reduction across a wide range of clinical studies

Procedural Elegance

Predictability and precision meet the needs of your practice

Proven Safety

Safety profile similar to cataract surgery alone

All With the Exceptional Customer Support You’ve Come to Expect From Glaukos

Explore Patient Resources for Glaucoma
Treatment Options

iStent infinite^® is indicated for use in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed. Through this procedure, you may be able to provide your patients with better IOP control and a reduced dependence on medication.

View Patient Website

Contact Us Today to Integrate iStent infinite^® Into Your Practice

Complete the form to get started with offering iStent infinite^® to your patients.

Request More Info

"*" indicates required fields

Full Name*

Address*

City State / Province / Region

Email Address*

Message*

CAPTCHA

Comments

This field is for validation purposes and should be left unchanged.

Reference

Glaukos Data on File.

iStent infinite^® Important Safety Information

Indication for Use

The iStent infinite Trabecular Micro-Bypass System Model iS3 is intended to reduce intraocular pressure in adult patients diagnosed with primary open-angle glaucoma (POAG) currently treated with ocular hypotensive medication. The device can be implanted with or without cataract surgery.

Contraindications

The iStent infinite System is contraindicated under the following circumstances or conditions: In eyes with primary angle closure glaucoma, or secondary angle-closure glaucoma, including neovascular glaucoma, because the device would not be expected to work in such situations; In patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

Warnings

Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualisation that could lead to improper placement of the stent and pose a hazard.

MRI Information

The iStent infinite is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.

Precautions

The surgeon should monitor the patient postoperatively for proper maintenance of IOP. Three out of 61 participants (4.9%) in the pivotal clinical trial were phakic. Therefore, there is insufficient evidence to determine whether the clinical performance of the device may be different in those who are phakic versus in those who are pseudophakic.

Adverse Effects

The most common postoperative adverse events reported in the iStent infinite pivotal trial included IOP increase ≥ 10 mmHg vs. baseline IOP (8.2%), loss of BSCVA ≥ 2 lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss ≥ 2.5 dB (6.6%).

Caution

Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.

iStent infinite®